Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene's Q4 Revenues, Loss Rise

NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market Monday that its fourth-quarter revenues increased sharply as its net loss climbed on a change in fair value of derivative instruments related to warrants.

The San Diego-based molecular diagnostics developer brought in total revenues of $163,000 for the three months ended Dec. 31, compared to $34,000 for the fourth quarter of 2011.

Its net loss for the quarter was $6.3 million, or $.43 per share. Trovagene said that the loss was primarily driven by a $4.9 million, or $.33 per share, charge tied to a change in fair value of derivative instruments related to warrants. Its net loss for Q4 2011 was $1.3 million, or $.12 per share.

Trovagene's R&D costs for the quarter nearly doubled to $594,000 from $308,000 year over year, while its SG&A spending climbed to $1 million from $603,000.

For full-year 2012, Trovagene posted revenues of $450,000, up 75 percent from revenues of $257,000 in 2011.

During the year, Trovagene launched its urine-based molecular human papillomavirus test.

Its net loss for the year increased to $11.6 million, or $.89 per share, from $2.3 million, or $.23 per share.

The firm's R&D spending more than doubled to $1.9 million from $910,000, and its general and administrative costs jumped 48 percent to $3.4 million from $2.3 million.

Trovagene finished the year with $10.8 million in cash and cash equivalents.

The firm brought in net proceeds of $4.4 million from a private placement in the fourth quarter. In January it said that it was seeking to raise $6.1 million through a public offering of its stock.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.